Member Info for Wiggly

Huge. Already 4 x average.

To RAH, Tom the Bomb, Litte Gunner, David Brewer + many others and most importantly Myles McNulty!

Fantastic research.

This analysis shows that AVA6000 targets the release of doxorubicin to the tumour tissue at therapeutic levels which are much higher than the levels being detected in the bloodstream at the same timepoint.

I was hopeful of a positive RNS but this has blown the blo ody doors off!!

Truly amazing.

I'm convinced very positive news is coming but can we really look deep into the changes of this text?

What delay? The market is unconcerned and that speaks volumes.

Market doesn't care that CEO missed his guidance. Suggests we have a leak of some sorts, otherwise I think we'd be punished for the delay

But it is also Friday the 13th!!

Does CEO AS have a last-minute surprise in store?

Unless I missed it, Sujood did not call the RNS today, so not sure why anyone expected an RNS!

@Gemstar

'If Dr Smith and other key executives are at the Morgan conference in the States this week, they are not going to issue a seminal RNS until they return'

Surely AS knew he was attending the Morgan conference when he issued the Dec RNS advising early Jan update?

The chomping has commenced..

The wait gets harder each day. Hopefully AS drops an intraday RNS!

If the preCISION MoA is formally confirmed next week, how will this impact the risk profile/chance of success of the TMAC concept?

Its also not an unreasonable hypothesis to believe that:

1. Higher volume doses of Dox via AVA6K Vs straight dox
2. Improved targeting via Ava6k Vs straight Dox;

Will deliver vastly improved efficacy on the tumor (shrinkage/elimination)

Fingers crossed for all those taking part!

Rah,

I understand the point and I'm not expecting much/any data on efficacy. Confirmation of Dox in the tumor will suffice however...... If AVA6K is really targeted, there is a possibility of much larger volume of Dox hitting the TME than there would be with straight Dox. If this is the case (real possibility it is) then efficacy data might be off the chart Vs straight dox.

Patients with the following conditions are unable to be dosed with straight dox:

Bone marrow problem (eg, drug-induced myelosuppression)

Heart disease

Liver disease

I assume such patients would benefit from AVA6k and early efficacy would be apparent

You make a lot of good points, RAH, but I think you are wrong in this instance.

Scans will be regular for each patient and efficacy will be monitored bi weekly.

'Most patients on this trial will have previously been unresponsive to chemotherapy'

The above is not true. Most patients are likely too unwell to survive straight dox/chemo, hence are being offered chance to partake in this trial.

Can I be first to say it...

If I were to be trading Avacta at this stage (which I think would be madness) .... I certainly wouldn't want to be out this weekend!

If you held pre trial/first dose you certainly do not need any reassurance at this stage!

If this really is a new addition (I cannot tell) then it is HUGE news !!